TABLE 5.
RT inhibitors AZT and tenofovir inhibit de novo infection by HTLV-1a
| Condition or treatment | Mouse | Proviral load (%)
|
Cell count (106) | |
|---|---|---|---|---|
| Lavage specimen | Spleen | |||
| Untreated | C1 | 4.2 | 1.1 | 1.6 |
| C2 | 0.7 | 0.0 | 12.5 | |
| C3 | 0.0 | 0.0 | 19.0 | |
| C4 | 5.9 | 0.6 | 6.0 | |
| C5 | 0.1 | 0.1 | 4.8 | |
| Tenofovir | T1 | 0.0 | 0.0 | 5.2 |
| T2 | 0.0 | 0.0 | 9.2 | |
| T3 | 0.0 | 0.0 | 1.7 | |
| T4 | 0.0 | 0.0 | 8.8 | |
| T5 | 0.0 | 0.0 | 4.0 | |
| AZT | A1 | 0.0 | 0.0 | 2.6 |
| A2 | 0.0 | 0.0 | 3.6 | |
| A3 | 0.0 | 0.0 | 4.5 | |
| A4 | 0.0 | 0.0 | 2.2 | |
| A5 | 0.0 | 0.0 | 2.3 | |
a
After human PBMC transfer and MT-2 inoculation (103 cells/mouse), mice were immediately subjected to antiretroviral therapy with AZT or tenofovir for 12 days. The control group was injected with PBS instead. Proviral loads were determined in cells recovered from the abdominal cavity and spleens. The total numbers of cells recovered from spleens are also shown.